Citations

Showing 10 of 108104 citations.

Prognostic Value of Preclinical Markers after Radiotherapy of Metastatic Spinal Cord Compression—An Additional Analysis of Patients from Two Prospective Trials
Rades, Dirk , Cacicedo, Jon , Lomidze, Darejan, Al-Salool, Ahmed , Grošelj, Blaž , Schild, Steven E. , Šegedin, Barbara

Mayo Clinic

Cancers | May 22, 2022 | Volume: 14 | Issue: 10 | Pages: 2547

10.3390/cancers14102547 | PMID 35626151 Get It

For optimal personalization of treatment for metastatic spinal cord compression (MSCC), the patient’s survival prognosis should be considered. Estimation of survival can be facilitated by prognostic factors. This study investigated the prognostic value of pre-treatment preclinical markers, namely hemoglobin, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lactate dehydrogenase (LDH), and c-reactive protein (CRP), in 190 patients from two prospective trials who had poor or intermediate survival prognoses and were irradiated for MSCC with motor deficits. In addition, clinical factors including radiation regimen, age, gender, tumor type, interval from tumor diagnosis to MSCC, number of affected vertebrae, visceral metastases, other bone metastases, time developing motor deficits, ambulatory status, sensory function, and sphincter function were evaluated. On univariate analyses, NLR (p = 0.033), LDH (p < 0.001), CRP (p < 0.001), tumor type (p < 0.001), pre-radiotherapy ambulatory status (p < 0.001), and sphincter function (p = 0.011) were significant. In the subsequent Cox regression analysis, LDH (p = 0.007), CRP (p = 0.047), tumor type (p = 0.003), and ambulatory status (p = 0.010) maintained significance. In addition to clinical factors, preclinical markers may help in estimating the survival of patients irradiated for MSCC. Additional prospective trials are warranted.
Immune reconstitution inflammatory syndrome in a non‐HIV immunocompromised patient with Pneumocystis Jirovecii pneumonia
Prada, Libardo Rueda , Razonable, Raymund R. , Rueda Prada, Libardo , Razonable, Raymund R

Mayo Clinic

Transplant Infectious Disease | May 22, 2022 | Volume: 24 | Issue: 4 | Pages: No page available

10.1111/tid.13856 | PMID 35598073 Get It

Deep Brain Stimulation for Tremor: Direct Targeting of a Novel Imaging Biomarker
Middlebrooks, Erik H. , Tipton, Philip W. , Greco, Elena , Mendez, Julio A., Uitti, Ryan J. , Tipton, Philip W , Okromelidze, Lela , Uitti, Ryan, Middlebrooks, Erik H , Grewal, Sanjeet S. , Greco, Elena

Mayo Clinic

Annals of Neurology | May 21, 2022 | Volume: 92 | Issue: 2 | Pages: 341-342

10.1002/ana.26422 | PMID 35596936 Get It

Organoids and regenerative hepatology
Jalan‐Sakrikar, Nidhi , Brevini, Teresa , Huebert, Robert C. , Sampaziotis, Fotios , Huebert, Robert , Sampaziotis, Fotis , Sakrikar, Nidhi Jalan

Mayo Clinic

Hepatology | May 21, 2022 | Volume: 77 | Issue: 1 | Pages: 305-322

10.1002/hep.32583 | PMID 35596930 Get It

The burden of liver diseases is increasing worldwide, with liver transplantation remaining the only treatment option for end‐stage liver disease. Regenerative medicine holds great potential as a therapeutic alternative, aiming to repair or replace damaged liver tissue with healthy functional cells. The properties of the cells used are critical for the efficacy of this approach. The advent of liver organoids has not only offered new insights into human physiology and pathophysiology, but also provided an optimal source of cells for regenerative medicine and translational applications. Here, we discuss various historical aspects of 3D organoid culture, how it has been applied to the hepatobiliary system, and how organoid technology intersects with the emerging global field of liver regenerative medicine. We outline the hepatocyte, cholangiocyte, and nonparenchymal organoids systems available and discuss their advantages and limitations for regenerative medicine as well as future directions.
The Development of Novel Drug Treatments for Stroke Patients: A Review
Frank, Dmitry , Boyko, Matthew , Gruenbaum, Benjamin F. , Boyko, Matthew , Gruenbaum, Benjamin Fredrick , Zlotnik, Alexander Anatolievich

Mayo Clinic

International Journal of Molecular Sciences | May 21, 2022 | Volume: 23 | Issue: 10 | Pages: 5796

10.3390/ijms23105796 | PMID 35628606 Get It

Acute ischemic stroke is a critical condition that can result in disability and death. The consequences of this medical condition depend on various factors, including the size of the stroke, affected brain region, treatment onset, and the type of treatment. The primary objective of stroke treatment is to restart ischemic penumbra tissue perfusion and reduce infarct volume by sustaining blood flow. Recent research on the condition’s pathological pathways and processes has significantly improved treatment options beyond restoring perfusion. Many studies have concentrated on limiting injury severity via the manipulation of molecular mechanisms of ischemia, particularly in animal research. This article reviews completed and ongoing research on the development of acute ischemic stroke drugs. This study focuses on three main categories of antithrombotic drugs, thrombolytic drugs, and neuroprotective agents. The paper outlines findings from animal and clinical trials and explores the working mechanisms of these drugs.
COVLIAS 1.0Lesion vs. MedSeg: An Artificial Intelligence Framework for Automated Lesion Segmentation in COVID-19 Lung Computed Tomography Scans
Suri, Jasjit S. , Agarwal, Sushant , Chabert, Gian Luca , Carriero, Alessandro , Paschè, Alessio , Saba, Luca , Mehmedović, Armin , Faa, Gavino , Singh, Inder M. , Turk, Monika, Chadha, Paramjit S., Johri, Amer M. , Khanna, Narendra N. , Laird, John R. , Pareek, Gyan , Miner, Martin , Sobel, David , Balestrieri, Antonella , Sfikakis, Petros P. , Tsoulfas, George, Protogerou, Athanase D. , Misra, Durga Prasanna , Agarwal, Vikas , Teji, Jagjit S. , Al-Maini, Mustafa , Dhanjil, Surinder, Rathore, Vijay , Fatemi, Mostafa , Krishnan, Pudukode R., Nagy, F. , Fouda, Mostafa M. , Naidu, Subbaram, Višković, Klaudija , Kalra, Manudeep, Mehmedović, Armin , Faa, Gavino , Sobel, David W , Tsoulfas, George , Protogerou, Athanasios , Agarwal, Vikas , Fatemi, Mostafa , Alizad, Azra , Ferenc, Nagy , Fouda, Mostafa M , Naidu, Subbaram , Viskovic, Klaudija , Misra, Durga Prasanna , Agarwal, Sushant , Suri, Jasjit S. , Danna, Pietro , Saba, Luca , Mavrogeni, Sophie , Kitas, George D. , Nicolaides, Andrew , Sharma, Aditya , Alizad, Azra , Ruzsa, Zoltán

Mayo Clinic

Diagnostics | May 21, 2022 | Volume: 12 | Issue: 5 | Pages: 1283

10.3390/diagnostics12051283 | PMID 35626438 Get It

Background: COVID-19 is a disease with multiple variants, and is quickly spreading throughout the world. It is crucial to identify patients who are suspected of having COVID-19 early, because the vaccine is not readily available in certain parts of the world. Methodology: Lung computed tomography (CT) imaging can be used to diagnose COVID-19 as an alternative to the RT-PCR test in some cases. The occurrence of ground-glass opacities in the lung region is a characteristic of COVID-19 in chest CT scans, and these are daunting to locate and segment manually. The proposed study consists of a combination of solo deep learning (DL) and hybrid DL (HDL) models to tackle the lesion location and segmentation more quickly. One DL and four HDL models—namely, PSPNet, VGG-SegNet, ResNet-SegNet, VGG-UNet, and ResNet-UNet—were trained by an expert radiologist. The training scheme adopted a fivefold cross-validation strategy on a cohort of 3000 images selected from a set of 40 COVID-19-positive individuals. Results: The proposed variability study uses tracings from two trained radiologists as part of the validation. Five artificial intelligence (AI) models were benchmarked against MedSeg. The best AI model, ResNet-UNet, was superior to MedSeg by 9% and 15% for Dice and Jaccard, respectively, when compared against MD 1, and by 4% and 8%, respectively, when compared against MD 2. Statistical tests—namely, the Mann–Whitney test, paired t-test, and Wilcoxon test—demonstrated its stability and reliability, with p < 0.0001. The online system for each slice was <1 s. Conclusions: The AI models reliably located and segmented COVID-19 lesions in CT scans. The COVLIAS 1.0Lesion lesion locator passed the intervariability test.
Artificial Intelligence Enhances Diagnostic Flow Cytometry Workflow in the Detection of Minimal Residual Disease of Chronic Lymphocytic Leukemia
Salama, Mohamed E. , Otteson, Gregory E., Camp, Jon J. , Seheult, Jansen N. , Holmes, David R. , Olteanu, Horatiu , Shi, Min , Olteanu, Horatiu , Shi, Min , Seheult, Jansen N , Jevremović, Dragan , Holmes, David R.

Mayo Clinic

Cancers | May 21, 2022 | Volume: 14 | Issue: 10 | Pages: 2537

10.3390/cancers14102537 | PMID 35626140 Get It

Flow cytometric (FC) immunophenotyping is critical but time-consuming in diagnosing minimal residual disease (MRD). We evaluated whether human-in-the-loop artificial intelligence (AI) could improve the efficiency of clinical laboratories in detecting MRD in chronic lymphocytic leukemia (CLL). We developed deep neural networks (DNN) that were trained on a 10-color CLL MRD panel from treated CLL patients, including DNN trained on the full cohort of 202 patients (F-DNN) and DNN trained on 138 patients with low-event cases (MRD < 1000 events) (L-DNN). A hybrid DNN approach was utilized, with F-DNN and L-DNN applied sequentially to cases. “Ground truth” classification of CLL MRD was confirmed by expert analysis. The hybrid DNN approach demonstrated an overall accuracy of 97.1% (95% CI: 84.7–99.9%) in an independent cohort of 34 unknown samples. When CLL cells were reported as a percentage of total white blood cells, there was excellent correlation between the DNN and expert analysis [r > 0.999; Passing–Bablok slope = 0.997 (95% CI: 0.988–0.999) and intercept = 0.001 (95% CI: 0.000–0.001)]. Gating time was dramatically reduced to 12 s/case by DNN from 15 min/case by the manual process. The proposed DNN demonstrated high accuracy in CLL MRD detection and significantly improved workflow efficiency. Additional clinical validation is needed before it can be fully integrated into the existing clinical laboratory practice.
Development and Early Experience of a Primary Care Learning Collaborative in a Large Health Care System
Erickson, Rodney A. , Chavez, Augustine , Cristiani, Valeria, DeJesus, Ramona S. , Laabs, Susan, Presutti, R. John , Rosas, Steven , Westfall, Erin , Witt, Terrence J. , Erickson, Rodney , Chavez, Augustine S , DeJesus, R S , Presutti, Richard J , Rosas, Steven L , Westfall, Erin , Witt, Terrence , Thacher, Thomas D , Dabrh, Abd Moain Abu , Thacher, Tom D.

Mayo Clinic

Journal of Primary Care & Community Health | May 21, 2022 | Volume: 13 | Issue: No issue available | Pages: No page available

10.1177/21501319221089775 | PMID 35603490 Get It

Introduction: Primary care clinicians are presented with hundreds of new clinical recommendations and guidelines. To consider practice change clinicians must identify relevant information and develop a contextual framework. Too much attention to information irrelevant to one’s practice results in wasted resources. Too little results in care gaps. A small group of primary care clinicians in a large health system sought to address the problem of vetting new information and providing peer reviewed context. This was done by engaging colleagues across the system though a primary care learning collaborative. Methods: The collaborative was a grass roots initiative between community and academic-based clinicians. They invited all the system’s primary care clinicians to participate. They selected new recommendations or guidelines and used surveys as the principal communication instrument. Surveys shared practice experience and also invited members to give narrative feedback regarding their acceptance of variation in care relate to the topic. A description of the collaborative along with its development, processes, and evolution are discussed. Process changes to address needs during the COVID-19 pandemic including expanded information sharing was necessary. Results: Collaborative membership reached across 5 states and included family medicine, internal medicine, and pediatrics. Members found involvement with the collaborative useful. Less variation in care was thought important for public health crises: the COVID pandemic and opioid epidemic. Greater practice variation was thought acceptable for adherence to multispecialty guidelines, such as diabetes, lipid management, and adult ADHD care. Process changes during the pandemic resulted in more communications between members to avoid practice gaps. Conclusion: An internet-based learning collaborative in a health system had good engagement from its members. Using novel methods, it was able to provide members with feedback related to the importance of new practice recommendations as perceived by their peers. Greater standardization was thought necessary when adopting measures to address public health crisis, and less necessary when addressing multispecialty guidelines. By employing a learning collaborative, this group was able to keep members interested and engaged. During the first year of the COVID pandemic the collaborative also served as a vehicle to share timely information.
Infectious complications in acute graft‐versus‐host disease after liver transplantation
Chesdachai, Supavit , Yetmar, Zachary A. , Watt, Kymberly D. , Aqel, Bashar , Yang, Liu , Beam, Elena , Udompap, Prowpanga , Yetmar, Zachary A , Beam, Elena , Chesdachai, Supavit , Aqel, Bashar A. , Yang, Liu

Mayo Clinic

Transplant Infectious Disease | May 21, 2022 | Volume: 24 | Issue: 4 | Pages: No page available

10.1111/tid.13843 | PMID 35596686 Get It

AbstractGraft‐versus‐hostdisease (GVHD) following liver transplantation (LT) is rare but can lead tosignificant mortality. The leading cause of death following GVHD diagnosis isinfectious complications. However, there is a lack of clear descriptions concerning infection and antimicrobial management patterns. Our study aims toprovide the focused details of all infectious complications of acute GVHDfollowing LT. We retrospectively reviewed all adult LT recipients with acute GVHD at Mayo Clinic's Transplant Centers from January 1, 2010, to December 31, 2021. Detailed characteristics of infection in each case were described. Among 4,585 LTs performed during this period, 12 (0.3%) patients developed acuteGVHD. The median time from transplantation to GVHD diagnosis was 49.0 days [IQR 31.5–99.0]. Ten (83.3%) patients developed severe infections leading tomortality. The most common cause of infection was nosocomial bacteremia fromenteric bacteria such as vancomycin‐resistant enterococci and gram‐negative bacilli. Other infections included breakthrough invasive fungal infections,cytomegalovirus (CMV) reactivation, and Clostridioides difficile colitis. Antimicrobial prophylaxis strategies in most cases were based on the degree of neutropenia—these include levofloxacin for bacterial prophylaxis, nebulized pentamidine for Pneumocystis jiroveci pneumonia prophylaxis, posaconazole for invasive fungal prophylaxis, and valganciclovir based on CMVstatus. All GVHD patients with severe infections succumbed to thesecomplications. Ourstudy reiterates that despite prophylaxis, infectious complications in GVHDfollowing LT are common and lead to exceptionally high mortality. Individualizedantimicrobial treatment, prophylaxis and monitoring strategies remain a criticalcomponent of GVHD management. Further study to optimize these practices isrequired. image
Physical Frailty and Brain White Matter Abnormalities: The Atherosclerosis Risk in Communities Study
Ducca, Emma L., Gómez, Gabriela , Palta, Priya, Sullivan, Kevin , Windham, B. Gwen , Sullivan, Kevin J , Jack, Clifford R. , Knopman, David S. , Gottesman, Rebecca F. , Walston, Jeremy D , Walker, Keenan A.

Mayo Clinic

The Journals of Gerontology: Series A | May 21, 2022 | Volume: 78 | Issue: 2 | Pages: 357-364

10.1093/gerona/glac111 | PMID 35596270 Get It

AbstractBackgroundPhysical frailty is associated with increased risk for dementia and other neurologic sequelae. However, the neurobiological changes underlying frailty and frailty risk remain unknown. We examined the association of cerebral white matter structure with current and future frailty.MethodsAtherosclerosis Risk in Communities Study Neurocognitive Study participants who underwent 3T brain MRI were included. Frailty status was classified according to the Fried criteria. Cerebral white matter integrity was defined using white matter hyperintensity (WMH) volume and microstructure, measured using diffusion tensor imaging fractional anisotropy (FA) and mean diffusivity (MD). Multivariable linear regression was used to relate baseline frailty to white matter structure; multivariable logistic regression was used to relate baseline white matter to frailty risk among participants nonfrail at baseline.ResultsIn the cross-sectional analysis (N = 1 754; mean age: 76 years), frailty was associated with greater WMH volume, lower FA, and greater MD. These associations remained consistent after excluding participants with a history of stroke or dementia. Among participants nonfrail at baseline who completed follow-up frailty assessment (N = 1 379; 6.6-year follow-up period), each standard deviation increase in WMH volume was associated with 1.46 higher odds of frailty at follow-up. Composite FA and MD measures were not associated with future frailty; however, secondary analyses found several significant white matter tract-specific associations with frailty risk.ConclusionThe current study demonstrates a robust association of WMH volume with current and future frailty. Although measures of white matter microstructure were altered in frail individuals, these measures were not generally associated with progression from nonfrail to frail status.